TipRanks
Markets are volatile, there can be no doubt. So far this month, the S&P 500 has fallen 9% from its peak. The tech-heavy NASDAQ, which had led the gainers all summer, is now leading the on the fall, having lost 11% since September 2. The three-week tumble has investors worried that we may be on the brink of another bear market.The headwinds are strong. The usual September swoon, the upcoming election, doubts about another round of economic stimulus all are putting downward pressure on the stock markets.Which doesnt mean that there are no opportunities. As the old saw goes, Bulls and bears can both make money, while the pigs get slaughtered. A falling market may worry investors, but a smart strategy can prevent the portfolio from losing too much long-term value while maintaining a steady income. Dividend stocks, which feed into the income stream, can be a key part of such a strategy.Using the data available in the TipRanks database, weve pulled up three stocks with high yields from 7% to 11%, or up to 6 times the average dividend found on the S&P 500 index. Even better, these stocks are seen as Strong Buys by Wall Streets analysts. Lets find out why.Williams Companies (WMB)We start with Williams Companies, an Oklahoma-based energy company. Williams controls pipelines connecting Rocky Mountain natural gas fields with the Pacific Northwest region, and Appalachian and Texan fields with users in the Northeast and transport terminals on the Gulf Coast. The companys primary operations are the processing and transport of natural gas, with additional ops in crude oil and energy generation. Williams handles nearly one-third of all US commercial and residential natural gas use.The essential nature of Williams business really, modern society simply cannot get along without reliable energy sources has insulated the company from some of the economic turndown in 1H20. Quarterly revenues slid from $2.1 billion at the end of last year to $1.9 billion in Q1 and $1.7 billion in Q2. EPS in the first half was 26 cents for Q1 and 25 cents for Q2 but this was consistent with EPS results for the previous three quarters. The generally sound financial base supported the companys reliable dividend. Williams has been raising that payment for the past four years, and even the corona crisis could not derail it. At 40 cents per common share, the dividend annualizes to $1.60 and yields an impressive 7.7%. The next payment is scheduled for September 28.Truist analyst Tristan Richardson sees Williams as one of the midstream sectors best positioned companies.We continue to look to WMB as a defensive component of midstream and favor its 2H prospects as broader midstream grasps at recovery Beyond 2020 we see the value proposition as a stable footprint with free cash flow generation even in the current environment. We also see room for incremental leverage reduction throughout our forecast period on scaled back capital plans and even with the stable dividend. We look for modestly lower capex in 2021, however unlike more G&P oriented midstream firms, we see a project backlog in downstream that should support very modest growth, Richardson noted.Accordingly, Richardson rates WMB shares as a Buy, and his $26 price target implies a 30% upside potential from current levels. (To watch Richardsons track record, click here)Overall, the Strong Buy analyst consensus rating on WMB is based on 11 Buy reviews against just a single Hold. The stocks current share price is $19.91 and the average price target is $24.58, making the one-year upside potential 23%. (See WMB stock analysis on TipRanks)Magellan Midstream (MMP)The second stock on our list is another midstream energy company, Magellan. This is another Oklahoma-based firm, with a network of assets across much of the US from the Rocky Mountains to the Mississippi Valley, and into the Southeast. Magellans network transports crude oil and refined products, and includes Gulf Coast export shipping terminals.Magellan's total revenues rose sequentially to $782.8 in Q1, and EPS came in at $1.28, well above the forecast. These numbers turned down drastically in Q2, as revenue fell to $460.4 million and EPS collapsed to 65 cents. The outlook for Q3 predicts a modest recovery, with EPS forecast at 85 cents. The company strengthened its position in the second quarter with an issue of 10-year senior notes, totaling $500 million, at 3.25%. This reduced the companys debt service payments, and shored up liquidity, making possible the maintenance of the dividend.The dividend was kept steady at $1.0275 per common share quarterly. Annualized, this comes to $4.11, a good absolute return, and gives a yield of 11.1%, giving MMP a far higher return than Treasury bonds or the average S&P-listed stock.Well Fargo analyst Praneeth Satish believes that MMP has strong prospects for recovery. [We] view near-term weakness in refined products demand as temporary and recovering. In the interim, MMP remains well positioned given its strong balance sheet and liquidity position, and ratable cash flow stream Satish goes on to note that the dividend appears secure for the near-term: The company plans to maintain the current quarterly distribution for the rest of the year.In line with this generally upbeat outlook, Satish gives MMP an Overweight (i.e. Buy) rating, and a $54 price target that implies 57% growth in the coming year. (To watch Satishs track record, click here)Net net, MMP shares have a unanimous Strong Buy analyst consensus rating, a show of confidence by Wall Streets analyst corps. The stock is selling for $33.44, and the average price target of $51.13 implies 53% growth in the year ahead. (See MMP stock analysis on TipRanks)Ready Capital Corporation (RC)The second stock on our list is a real estate investment trust. No surprise finding one of these in a list of strong dividend payers REITs have long been known for their high dividend payments. Ready Capital, which focuses on the commercial mortgage niche of the REIT sector, has a portfolio of loans in real estate securities and multi-family dwellings. RC has provided more than $3 billion in capital to its loan customers.In the first quarter of this year, when the coronavirus hit, the economy turned south, and business came to a standstill, Ready Capital took a heavy blow. Revenues fell by 58%, and Q1 EPS came in at just one penny. Things turned around in Q2, however, after the company took measures including increasing liquidity, reducing liabilities, and increasing involvement in government-sponsored lending to shore up business. Revenues rose to $87 million and EPS rebounded to 70 cents.In the wake of the strong Q2 results, RC also started restoring its dividend. In Q1 the company had slashed the payment from 40 cents to 25 cents; in the most recent declaration, for an October 30 payment, the new dividend is set at 30 cents per share. This annualizes to $1.20 and gives a strong yield of 9.9%.Crispin Love, writing from Piper Sandler, notes the companys success in getting back on track.Given low interest rates, Ready Capital had a record $1.2B in residential mortgage originations versus our $1.1B estimate. Gain on sale margins were also at record levels. We are calculating gain on sale margins of 3.7%, up from 2.4% in 1Q20, Love wrote.In a separate note, written after the dividend declaration, Love added, We believe that the Board's actions show an increased confidence for the company to get back to its pre-pandemic $0.40 dividend. In recent earnings calls, management has commented that its goal is to get back to stabilized earnings above $0.40, which would support a dividend more in-line with pre-pandemic levels.To this end, Love rates RC an Overweight (i.e. Buy) along with a $12 price target, suggesting an upside of 14%. (To watch Loves track record, click here)All in all, Ready Capital has a unanimous Strong Buy analyst consensus rating, based on 4 recent positive reviews. The stock has an average price target of $11.50, which gives a 9% upside from the current share price of $10.51. (See RC stock analysis on TipRanks)To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
The rest is here:
PTC Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit - Yahoo Finance
- A Year of DMD Gene Therapy Trial Failures - AJMC.com Managed Markets Network - November 3rd, 2024
- Hemophilia B: Gene Therapy Shows Promise - Medscape - November 3rd, 2024
- Around the Helix: Cell and Gene Therapy Company Updates October 30, 2024 - CGTLive - November 3rd, 2024
- 2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers - PharmaVoice - November 3rd, 2024
- Cell therapy weekly: support for commercialization of complex therapies - RegMedNet - November 3rd, 2024
- Lexeo shares early data on Alzheimers gene therapy - Endpoints News - November 3rd, 2024
- Medicaid Aiming to Improve Patient Access to High-Cost Therapies - AJMC.com Managed Markets Network - November 3rd, 2024
- The Significance of Gene Therapy in Neuromuscular Medicine at the 2025 MDA Conference: Paul Melmeyer, MPP - Neurology Live - November 3rd, 2024
- OHSU researchers identify gene that could be key to future HIV vaccine - OHSU News - November 3rd, 2024
- Purespring gene therapy reduces kidney scarring in mice and is stably expressed in pigs - Fierce Biotech - November 3rd, 2024
- Data Roundup: October 2024 Features Update for TCR-Based Autologous Cell Therapy in Melanoma, the First Clinical Demonstration of Therapeutic RNA... - November 3rd, 2024
- NewBiologix Launches Xcell to Accelerate, Optimize, and Scale Gene and Cell Therapy Production - Business Wire - November 3rd, 2024
- Vertex Pharmaceuticals and CRISPR Therapeutics Casgevy: the 200 Best Inventions of 2024 - TIME - November 3rd, 2024
- Addressing gene and cell therapy commercialization challenges - TechTarget - November 3rd, 2024
- University of Pennsylvania gene therapy spinout Interius BioTherapeutics doses patient, achieves CAR therapy first - The Business Journals - November 3rd, 2024
- Roche will aim to tackle gene therapy challenges through Dyno deal - The Pharma Letter - November 3rd, 2024
- Behind the Breakthroughs: How to Turn $1,000,000 CAR Ts into Real Medicines - Inside Precision Medicine - November 3rd, 2024
- Terumo automates manufacturing to expand cell & gene therapies - European Pharmaceutical Manufacturer - November 3rd, 2024
- 12-Year-Old Leaves Washington DC Hospital As The First Patient To Receive Approved Gene Therapy For Sickle Cell Disease - AfroTech - November 3rd, 2024
- Lexeo Therapeutics Announces Positive Interim Data for - GlobeNewswire - November 3rd, 2024
- New FDA designations granted to NCATS for rare disease therapies. - NCBI - October 22nd, 2024
- $1.8 Million Awarded to Study the Durability of Gene Therapy - University of Arkansas Newswire - October 22nd, 2024
- By the numbers: US leads charge of cell and gene therapies - BioWorld Online - October 22nd, 2024
- University of Arkansas Researcher Awarded $1.8M for Gene Therapy Study - Arkansas Business - October 22nd, 2024
- Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - StockTitan - October 22nd, 2024
- Around the Helix: Cell and Gene Therapy Company Updates October 16, 2024 - CGTLive - October 22nd, 2024
- Japan mulls ways to boost cell, gene therapy approvals - BioWorld Online - October 22nd, 2024
- A New Type of Gene Therapy Shows Promise for Treating Retinitis Pigmentosa - Managed Healthcare Executive - October 22nd, 2024
- Buy, Sell, Hold: Cell and Gene Therapy - Part 2 - BioPharm International - October 22nd, 2024
- When a Miracle Cure Is Left on the Shelf - Bloomberg - October 22nd, 2024
- Genethon to Showcase the Latest Advances in Gene Therapies for Multiple Diseases at the ESGCT 31 - Business Wire - October 22nd, 2024
- MeiraGTx's gene therapy improves motor function and quality of life in phase 2 Parkinson's trial - Fierce Biotech - October 22nd, 2024
- 5 Sickle Cell Therapies to Watch Following Pfizers Oxbryta Exit - BioSpace - October 22nd, 2024
- Fiocruz and GEMMABio announce partnership for the development of gene therapies - Fiocruz - October 22nd, 2024
- JPMA on Japans Biotech Industry: Cancer, Cardiovascular, and Aging Lead Diseases; Antibody, Cell, and Gene Therapies Top the Innovation List -... - October 22nd, 2024
- Cell and Gene Therapy Clinical Trial Market is expected to reach USD 119.3 Billion by 2032 at a 24.9% of CAGR - PharmiWeb.com - October 22nd, 2024
- Buy, Sell, Hold: Cell and Gene Therapy - Part 3 - Pharmaceutical Technology Magazine - October 22nd, 2024
- The role of quality assurance in accelerating drug development for emerging therapies - pharmaphorum - October 22nd, 2024
- Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - The Manila Times - October 22nd, 2024
- Nucleic Acid and Gene Therapies in Neuromuscular Disorders Market is projected to grow at a CAGR of - PharmiWeb.com - October 22nd, 2024
- Gene therapy: advances, challenges and perspectives - PMC - October 6th, 2024
- Meeting on the Mesa to Highlight Cell and Gene Therapy Opportunities, Challenges - BioSpace - October 6th, 2024
- Ferring opens doors to Finnish manufacturing hub as supply of its bladder cancer gene therapy continues to grow - FiercePharma - October 6th, 2024
- Meet Boston's National STEM Champion who's a junior in high school studying gene therapy - CBS Boston - October 6th, 2024
- Gene therapy research offers hope for kids with life-altering condition - WCVB Boston - October 6th, 2024
- Is gene therapy the next big step in vision loss treatment? - Medical News Today - October 6th, 2024
- Protein's Role in Insulin Signaling Could Have Implications for Gene Therapy - AJMC.com Managed Markets Network - October 6th, 2024
- Scientists overcome major challenge in gene therapy and drug delivery - News-Medical.Net - October 6th, 2024
- Innovative gene therapy for hemophilia - healthcare-in-europe.com - October 6th, 2024
- The Largest Network of Research Sites Vetted to Execute Complexities of Cell & Gene Therapy (CGT) Trials Now Includes 1,500 Sites - PR Newswire - October 6th, 2024
- Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now - Quartz - October 6th, 2024
- Cell therapy weekly: Promising Phase I results for Parkinsons disease cell therapy - RegMedNet - October 6th, 2024
- Targeting CREB-binding protein (CBP) abrogates colorectal cancer stemness through epigenetic regulation of C-MYC - Nature.com - October 6th, 2024
- Forge Biologics Announces the FUEL AAV Manufacturing Platform to Provide Developers with a More Efficient Solution for Gene Therapy Production -... - October 6th, 2024
- Ninth Circuit Decision Marks Critical Legal Victory for U.S. FDA in Mission to Protect Patients from Unregulated Cell Therapy Products - PR Newswire - October 6th, 2024
- Gene therapy: What is it and how does it work? | Live Science - September 21st, 2024
- How Does Gene Therapy Work? Types, Uses, Safety - Healthline - September 21st, 2024
- In race to make gene therapy for age-related blindness, 4D Molecular announces positive results - STAT - September 21st, 2024
- Penn gene therapy pioneer Jim Wilson explains why he's leaving - The Business Journals - September 21st, 2024
- Whats the Meaning of Cure in Gene Therapy? - Managed Healthcare Executive - September 21st, 2024
- Ori doubles down on Charles River collaboration with promising new data on its automated cell therapy platform - FiercePharma - September 21st, 2024
- Doctors cured her sickle-cell disease. So why is she still in pain? - Nature.com - September 21st, 2024
- Gene Therapy Company Increases Focus on Mesothelioma Program - Mesothelioma.net Blog - September 21st, 2024
- Sickle cell gene therapies roll out slowly : Shots - Health News - NPR - September 21st, 2024
- Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies - BioSpace - September 21st, 2024
- Beacon Therapeutics Presents 36-Month Interim Results from Phase I/2 HORIZON Trial of AGTC-501 in Patients with XLRP - PR Newswire - September 21st, 2024
- Beacons Gene Therapy Shows Continued Promise in Trial - TipRanks - September 21st, 2024
- How stem cell and gene therapies are revolutionising healthcare - Express Healthcare - September 21st, 2024
- Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona - PR Newswire - September 21st, 2024
- 6-year-old Tennessee boy denied potentially life-saving gene therapy by insurance company - WCYB - September 21st, 2024
- Seeking a sickle cell cure: 12-year-old in DC is 1st patient in US to get new gene therapy - NBC Washington - May 24th, 2024
- Game-changer: The Hindu Editorial on approval for gene therapy to treat sickle cell disease and beta thalassemia - The Hindu - December 13th, 2023
- Early trials show promise for innovative gene therapy in lung cancer treatment - WJAR - October 16th, 2023
- Cell and Gene Therapy Manufacturing Quality Control Market Growing Trends and Technology Forecast to 2029 |... - SeeDance News - October 16th, 2023
- How Gene Therapy Can Cure or Treat Diseases | FDA - March 21st, 2023
- Genetic Therapies - What Are Genetic Therapies? | NHLBI, NIH - March 21st, 2023
- FDA approves novel gene therapy to treat patients with a rare form of ... - December 28th, 2022
- Gene Therapy - Discover How It Works Its Types And Applications - BYJUS - December 28th, 2022
- IVERIC bio Subsidiary Sells Assets of Gene Therapy Product Candidates for Treatment of Retinal Diseases - Marketscreener.com - December 28th, 2022
- Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th... - October 31st, 2022